vs
艾伯维（ABBV）与嘉德诺（BTSG）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是嘉德诺的4.7倍（$16.6B vs $3.6B）。艾伯维净利率更高（10.9% vs 2.2%，领先8.8%）。嘉德诺同比增速更快（16.3% vs 10.0%）。艾伯维自由现金流更多（$4.9B vs $193.9M）。过去两年嘉德诺的营收复合增速更高（17.4% vs 16.2%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
嘉德诺是美国跨国医疗服务企业，位列美国企业营收榜第15位，总部位于俄亥俄州都柏林。公司主营药品与医疗产品分销，服务覆盖超10万个网点，同时生产手套、手术服、流体管理产品等医用外科用品，还运营着规模位居前列的放射性药物网络。
ABBV vs BTSG — 直观对比
营收规模更大
ABBV
是对方的4.7倍
$3.6B
营收增速更快
BTSG
高出6.3%
10.0%
净利率更高
ABBV
高出8.8%
2.2%
自由现金流更多
ABBV
多$4.7B
$193.9M
两年增速更快
BTSG
近两年复合增速
16.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $3.6B |
| 净利润 | $1.8B | $77.1M |
| 毛利率 | 72.6% | 11.6% |
| 营业利润率 | 27.3% | 3.0% |
| 净利率 | 10.9% | 2.2% |
| 营收同比 | 10.0% | 16.3% |
| 净利润同比 | 8354.5% | 381.8% |
| 每股收益（稀释后） | $1.02 | $0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVBTSG
| Q4 25 | $16.6B | $3.6B | ||
| Q3 25 | $15.8B | $3.3B | ||
| Q2 25 | $15.4B | $3.1B | ||
| Q1 25 | $13.3B | $2.9B | ||
| Q4 24 | $15.1B | $3.1B | ||
| Q3 24 | $14.5B | $2.9B | ||
| Q2 24 | $14.5B | $2.7B | ||
| Q1 24 | $12.3B | $2.6B |
净利润ABBVBTSG
| Q4 25 | $1.8B | $77.1M | ||
| Q3 25 | $186.0M | $55.8M | ||
| Q2 25 | $938.0M | $28.2M | ||
| Q1 25 | $1.3B | $29.5M | ||
| Q4 24 | $-22.0M | $16.0M | ||
| Q3 24 | $1.6B | $-8.2M | ||
| Q2 24 | $1.4B | $19.9M | ||
| Q1 24 | $1.4B | $-45.8M |
毛利率ABBVBTSG
| Q4 25 | 72.6% | 11.6% | ||
| Q3 25 | 66.4% | 11.8% | ||
| Q2 25 | 71.8% | 11.9% | ||
| Q1 25 | 70.0% | 11.8% | ||
| Q4 24 | 70.9% | 13.8% | ||
| Q3 24 | 70.9% | 14.0% | ||
| Q2 24 | 70.9% | 14.2% | ||
| Q1 24 | 66.7% | 14.3% |
营业利润率ABBVBTSG
| Q4 25 | 27.3% | 3.0% | ||
| Q3 25 | 12.1% | 2.6% | ||
| Q2 25 | 31.7% | 1.5% | ||
| Q1 25 | 28.0% | 1.8% | ||
| Q4 24 | -9.9% | 2.6% | ||
| Q3 24 | 26.5% | 2.0% | ||
| Q2 24 | 27.6% | 2.3% | ||
| Q1 24 | 22.7% | 0.3% |
净利率ABBVBTSG
| Q4 25 | 10.9% | 2.2% | ||
| Q3 25 | 1.2% | 1.7% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 9.6% | 1.0% | ||
| Q4 24 | -0.1% | 0.5% | ||
| Q3 24 | 10.8% | -0.3% | ||
| Q2 24 | 9.5% | 0.7% | ||
| Q1 24 | 11.1% | -1.8% |
每股收益（稀释后）ABBVBTSG
| Q4 25 | $1.02 | $0.34 | ||
| Q3 25 | $0.10 | $0.26 | ||
| Q2 25 | $0.52 | $0.13 | ||
| Q1 25 | $0.72 | $0.14 | ||
| Q4 24 | $-0.03 | $0.11 | ||
| Q3 24 | $0.88 | $-0.04 | ||
| Q2 24 | $0.77 | $0.10 | ||
| Q1 24 | $0.77 | $-0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $88.4M |
| 总债务越低越好 | $58.9B | $2.5B |
| 股东权益账面价值 | $-3.3B | $1.9B |
| 总资产 | $134.0B | $6.4B |
| 负债/权益比越低杠杆越低 | — | 1.34× |
8季度趋势，按日历期对齐
现金及短期投资ABBVBTSG
| Q4 25 | $5.3B | $88.4M | ||
| Q3 25 | $5.7B | $140.3M | ||
| Q2 25 | $6.5B | $70.1M | ||
| Q1 25 | $5.2B | $52.3M | ||
| Q4 24 | $5.6B | $61.3M | ||
| Q3 24 | $7.3B | $36.0M | ||
| Q2 24 | $13.2B | $25.0M | ||
| Q1 24 | $18.1B | $58.0M |
总债务ABBVBTSG
| Q4 25 | $58.9B | $2.5B | ||
| Q3 25 | $63.0B | $2.5B | ||
| Q2 25 | $63.0B | $2.5B | ||
| Q1 25 | $64.5B | $2.5B | ||
| Q4 24 | $60.3B | $2.6B | ||
| Q3 24 | $58.5B | $2.7B | ||
| Q2 24 | $58.0B | $2.6B | ||
| Q1 24 | $63.8B | $2.6B |
股东权益ABBVBTSG
| Q4 25 | $-3.3B | $1.9B | ||
| Q3 25 | $-2.6B | $1.8B | ||
| Q2 25 | $-183.0M | $1.7B | ||
| Q1 25 | $1.4B | $1.7B | ||
| Q4 24 | $3.3B | $1.6B | ||
| Q3 24 | $6.0B | $1.6B | ||
| Q2 24 | $6.8B | $1.6B | ||
| Q1 24 | $8.0B | $1.6B |
总资产ABBVBTSG
| Q4 25 | $134.0B | $6.4B | ||
| Q3 25 | $133.9B | $6.0B | ||
| Q2 25 | $137.2B | $5.9B | ||
| Q1 25 | $136.2B | $5.8B | ||
| Q4 24 | $135.2B | $5.9B | ||
| Q3 24 | $143.4B | $5.8B | ||
| Q2 24 | $141.9B | $5.6B | ||
| Q1 24 | $148.9B | $5.7B |
负债/权益比ABBVBTSG
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | 45.44× | 1.50× | ||
| Q4 24 | 18.15× | 1.58× | ||
| Q3 24 | 9.70× | 1.65× | ||
| Q2 24 | 8.56× | 1.63× | ||
| Q1 24 | 7.97× | 1.64× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $231.6M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $193.9M |
| 自由现金流率自由现金流/营收 | 29.4% | 5.5% |
| 资本支出强度资本支出/营收 | 2.0% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.87× | 3.00× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $394.7M |
8季度趋势，按日历期对齐
经营现金流ABBVBTSG
| Q4 25 | $5.2B | $231.6M | ||
| Q3 25 | $7.0B | $107.9M | ||
| Q2 25 | $5.2B | $49.1M | ||
| Q1 25 | $1.6B | $101.6M | ||
| Q4 24 | $7.0B | $90.6M | ||
| Q3 24 | $5.4B | $27.2M | ||
| Q2 24 | $2.3B | $-15.2M | ||
| Q1 24 | $4.0B | $-78.9M |
自由现金流ABBVBTSG
| Q4 25 | $4.9B | $193.9M | ||
| Q3 25 | $6.6B | $92.2M | ||
| Q2 25 | $4.9B | $24.7M | ||
| Q1 25 | $1.4B | $84.0M | ||
| Q4 24 | $6.8B | $75.3M | ||
| Q3 24 | $5.2B | $7.2M | ||
| Q2 24 | $2.0B | $-39.0M | ||
| Q1 24 | $3.8B | $-100.7M |
自由现金流率ABBVBTSG
| Q4 25 | 29.4% | 5.5% | ||
| Q3 25 | 42.1% | 2.8% | ||
| Q2 25 | 31.7% | 0.8% | ||
| Q1 25 | 10.5% | 2.9% | ||
| Q4 24 | 44.7% | 2.5% | ||
| Q3 24 | 35.9% | 0.2% | ||
| Q2 24 | 14.0% | -1.4% | ||
| Q1 24 | 31.3% | -3.9% |
资本支出强度ABBVBTSG
| Q4 25 | 2.0% | 1.1% | ||
| Q3 25 | 2.4% | 0.5% | ||
| Q2 25 | 1.7% | 0.8% | ||
| Q1 25 | 1.8% | 0.6% | ||
| Q4 24 | 1.9% | 0.5% | ||
| Q3 24 | 1.7% | 0.7% | ||
| Q2 24 | 1.7% | 0.9% | ||
| Q1 24 | 1.6% | 0.8% |
现金转化率ABBVBTSG
| Q4 25 | 2.87× | 3.00× | ||
| Q3 25 | 37.76× | 1.93× | ||
| Q2 25 | 5.49× | 1.74× | ||
| Q1 25 | 1.27× | 3.44× | ||
| Q4 24 | — | 5.66× | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | -0.76× | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
BTSG
| Medicare D | $1.1B | 32% |
| Commercial Insurance | $879.8M | 25% |
| Medicare C | $641.2M | 18% |
| Provider Services | $394.2M | 11% |
| Medicaid | $301.4M | 8% |
| Medicare A | $150.5M | 4% |
| Private And Other | $44.0M | 1% |
| Medicare B | $19.5M | 1% |
| Pharmacy Solutions And Provider Services Segments | $19.0M | 1% |
